Robert Gut - 12 Jan 2026 Form 4 Insider Report for uniQure N.V. (QURE)

Role
Director
Signature
/s/ Christian Klemt, Attorney-in-Fact
Issuer symbol
QURE
Transactions as of
12 Jan 2026
Net transactions value
-$379,718
Form type
4
Filing time
14 Jan 2026, 16:26:27 UTC
Previous filing
10 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Gut Robert Director C/O UNIQURE N.V., PAASHEUVELWEG 25A, AMSTERDAM, NETHERLANDS /s/ Christian Klemt, Attorney-in-Fact 14 Jan 2026 0001716268

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction QURE Ordinary Shares Options Exercise $250,765 +17,810 +44% $14.08 57,955 12 Jan 2026 Direct F1
transaction QURE Ordinary Shares Sale $422,191 -17,310 -30% $24.39 40,645 12 Jan 2026 Direct F1, F2
transaction QURE Ordinary Shares Sale $12,515 -500 -1.2% $25.03 40,145 12 Jan 2026 Direct F1, F3
transaction QURE Ordinary Shares Sale $195,777 -7,803 -19% $25.09 32,342 12 Jan 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction QURE Stock Option (Right to Buy) Options Exercise $0 -17,810 -100% $0.000000 0 12 Jan 2026 Ordinary Shares 17,810 $14.08 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported herein were effected pursuant to a sales plan adopted by the Reporting Person on July 8, 2025 and intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.02 to $25.00. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.02 to $25.04. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The Stock Option vested in full on June 15, 2023.